Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $19.70, moving -0.76% from the previous trading session.

J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study

Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.

Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study

Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.

Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid

Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.

AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting

AbbVie's (ABBV) key cancer drug, Imbruvica, in combination with Gazyva, gets FDA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in first-line setting.

Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results

Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.

Merck's Partner Gets FDA Nod for Herceptin Biosimilar

Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $18.76, moving +0.59% from the previous trading session.

6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019

Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $18.45 in the latest trading session, marking a +1.54% move from the prior day.

INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data

INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Teva Pharmaceutical Industries, Visa, American Express, Liberty Latin America and Sirius XM

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Teva Pharmaceutical Industries, Visa, American Express, Liberty Latin America and Sirius XM

Tirthankar Chakraborty headshot

5 Must-Watch Warren Buffett Stocks for 2019

We have selected five of Oracle of Omaha's favored companies that are likely to make the most of this year. Most of these companies belong to sectors such as health care, financials and communication services.

Regeneron, Sanofi Restructure Immuno-Oncology Collaboration

Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.

VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster

Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.

Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar

Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.

Generic Industry on Path to Recovery: 3 Hot Picks for 2019

The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.

Teva Stock Rises on Patent Settlement With Neos Therapeutics

Teva's (TEVA) shares rally as it enters into an agreement to settle all patent litigation related to its abbreviated new drug application for Neos Therapeutics' ADHD drug, Cotempla XR-ODT.

Company News For Dec 27, 2018

Companies In The News Are: TEVA,NEOS,JD,EXPE,INTC,MAR

Lilly's Shares Rise on Robust 2019 View, Dividend Hike

Eli Lilly's (LLY) shares rise 3% on an upbeat outlook for 2019. It also hikes quarterly dividend by 15%.

Allergan Drops, Stops Textured Breast Implant Sales in Europe

Allergan (AGN) halts the sale of its textured breast implants and tissue expanders in Europe. Stock declines.

Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Teva Reports Positive Top-Line Data for Migraine Candidate

Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.

Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug

Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.